1973

• The Central Research Center was established

1985

• Completed the construction of the Central Research Center building
• Commercialized Cefmetazone Injection, a freeze-dried injectable

1994

• Won the IR52 Jang Young-shil Award (Successful development of Ambroxol)
• Commercialized inflammatory analgesic Loxonin Tablet

2001

• Succeeded in developing the world's first radiopharmaceutical to treat liver cancer, "Milican Injection"
• Won the Dasan Technology Award
• Obtained the Certificate for being a World-Class Korean Product

2002

• "Milican Injection" included in "Top 10 New Technologies in Korea
• Won the Korea New Drug Award
• Won the Prime Minister Award for Industry-Academia Joint Research

2003

• Commercialized Vitachun Plus
• Won the Dongam Pharmaceutical Award (New Drug Development Category)
• Received the Bronze Medal, the Order of Industrial Service Merit

2004

• Succeeded in the synthesis of Pantoprazole (Gastric, duodenal ulcer treatment)

2007

• Transferred the technology of osteoporosis treatment (DW1350) (P&GP, USA)
• Transferred the technology of quinolone antimicrobial (DW224a) (Pacific Beach Biosciences, USA)

2008

• Transferred the technology of osteoporosis treatment (DW1350) (Teijin, Japan)

2010

• Completed the construction of the Yongin Research Center

2014

• Released Clzapin in the domestic market (Independent localization)

2015

• Zabolante received the NET certificate of the Ministry of Health and Welfare
• Zabolante, a new quinolone antimicrobial, received the Ministry of Food and Drug Safety's approval

2016

• Signed a license and supply contract for Zabolante with 12 countries in the Middle East and Africa

2017

• Signed a license and supply (sales) contract for Zabolante with China

2018

• Zabolante won the Korea New Drug Award

2022

• First functional probiotics for cognitive function improvement DW2009, approved by the Ministry of Food and Drug Safety